Reported about 15 hours ago
William Blair describes the complete response letter (CRL) from the FDA regarding Applied Therapeutics' (APLT) govorestat for galactosemia as an unexpected disappointment, leaving the future trajectory of the treatment unclear. While the rejection marks a significant setback, there's hope for gaining clarity through a potential Type-A meeting with the FDA. Following the news, APLT's stock plummeted by 71% in premarket trading.
Source: YAHOO